What Progress In The Rare Disease, Osteogenesis Imperfecta?

Two-year-old biotech Mereo BioPharma Group plc is planning to start a pivotal Phase IIb study in osteogenesis imperfecta patients in the first-half of this year with its anti-sclerostin antibody, BPS-804, and if the results are promising, EU patients could gain early access through the region’s adaptive pathways program.

Bone structure

Osteogenesis imperfecta, or brittle bone disease, is a rare condition that is more familiar than most to the general public, as it can have a debilitating effect on younger children and be distressing to parents, patients and family members. But the condition has few if any effective therapies on the market or in development, a fact that backs the acceptance of Mereo BioPharma Group Ltd.’s investigational osteogenesis imperfecta product BPS-804 into the European Medicines Agency’s adaptive pathways program, announced Feb. 20.

BPS-804 is a monoclonal antibody that stimulates the formation of bone by osteoblasts through inhibiting sclerostin, a protein that in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip